Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies

MT Newswires Live01-08

Evotec (EVO) said early Thursday its subsidiary, Just - Evotec Biologics, received a new grant from the Gates Foundation to help optimize monoclonal antibodies and other biological medicines.

Under the grant terms, the unit will leverage its molecular design suite of computational technologies, which integrate "advanced computational tools and high-throughput methodologies" to streamline the biologics development process, the company said.

The new investment will enable 10 new molecular design projects over the next three years, spanning the development of biotherapeutics that target multiple global health concerns.

Monoclonal antibodies are lab-made proteins that support the immune system in a targeted manner.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment